Study identification

PURI

https://redirect.ema.europa.eu/resource/106077

EU PAS number

EUPAS106076

Study ID

106077

Official title and acronym

Eptinezumab versus conventional preventive treatments as ≥2nd line prophylaxis of migraine – propensity score matched multiple cohort comparative retrospective longitudinal analyses of depersonalized 6-months real-world data of the German Pain e-Registry. (ESCAPE)

DARWIN EU® study

No

Study countries

Germany

Study description

ESCAPE is an exploratory, non-interventional, post-marketing, open-label, retrospective parallel-group, flexible-dose, comparative longitudinal 24-week multiple-cohort-study using depersonalized data of the German Pain e-Registry (GPeR, until September 30, 2022) to assess the effectiveness of the calcitonin gene-related peptide antagonist eptinezumab compared to conventional medications used for the prophylactic treatment in adult patients with migraine who are deemed to be in need of an alternative preventive medication according to the mutual / shared decision of the responsible physician and affected patients.

Study status

Finalised
Research institutions and networks

Institutions

Contact details

Michael Ueberall

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Other

More details on funding

IFNAP - Private Institute of Neurological Sciencess, O.Meany - MDPM GmbH
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable